Mapi Pharma has closed a $10 million (€9 million) Series A round to finance mid-phase trials of its once-a-month version of Teva's ($TEVA) blockbuster multiple ...
NESS ZIONA, Israel, July 15, 2019 (GLOBE NEWSWIRE) -- Mapi Pharma Ltd., a fully integrated, late-stage clinical development biopharmaceutical company announced today that is has signed a long term ...
The patent covers intermediate compounds and processes for the preparation of Fingolimod NESS ZIONA, Israel, Feb 18, 2014 (BUSINESS WIRE) -- Mapi Pharma Ltd. ("Mapi" or the "Company"), a developer of ...
NESS ZIONA, Israel, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Mapi Pharma Ltd., a fully integrated, late-stage clinical development biopharmaceutical company focused on introducing innovative long-acting ...
Mapi Pharma is nothing if not persistent. Having tried and failed twice to pull off an IPO on Nasdaq, the Israeli biopharma has arrived on Wall Street yet again in pursuit of $57.5 million (€51.2 ...
With the end of the year fast approaching, nations are looking for ways to secure enough supply of a potential COVID-19 vaccine to meet demand from their citizens. For Israeli drugmaker Mapi Pharma, ...
Once approved, this product could represent a significant milestone for patients with relapsing-remitting multiple sclerosis Mapi Pharma has completed an open-label Phase II clinical trial and is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results